Literature DB >> 24060211

Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor.

Masao Matsuoka1, Jun-ichirou Yasunaga.   

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) spreads primarily by cell-to-cell transmission. Therefore, HTLV-1 promotes the proliferation of infected cells to facilitate transmission. In HTLV-1 infected individuals, the provirus is present mainly in effector/memory T cells and Foxp3+ T cells. Recent study suggests that this immunophenotype is acquired by infected cells through the function of HTLV-1 bZIP factor (HBZ). Tax, which is encoded by the plus strand, is crucial for viral replication and de novo infection, while HBZ, encoded by the minus strand, is important for proliferation of infected cells. Importantly, HBZ and Tax have opposing functions in most transcription pathways. HBZ and Tax cooperate in elaborate ways to permit viral replication, proliferation of infected cells and propagation of the virus.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24060211     DOI: 10.1016/j.coviro.2013.08.010

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  44 in total

1.  TCF1 and LEF1 act as T-cell intrinsic HTLV-1 antagonists by targeting Tax.

Authors:  Guangyong Ma; Jun-ichirou Yasunaga; Hirofumi Akari; Masao Matsuoka
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

2.  RNA stability regulates human T cell leukemia virus type 1 gene expression in chronically-infected CD4 T cells.

Authors:  Hsin-Ching Lin; Peter J Simon; Riza M Ysla; Steven L Zeichner; Gary Brewer; Arnold B Rabson
Journal:  Virology       Date:  2017-05-04       Impact factor: 3.616

3.  miR-28-3p is a cellular restriction factor that inhibits human T cell leukemia virus, type 1 (HTLV-1) replication and virus infection.

Authors:  Xue Tao Bai; Christophe Nicot
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

4.  MAGI-1 expression is decreased in several types of human T-cell leukemia cell lines, including adult T-cell leukemia.

Authors:  Takashi Kozakai; Masahiko Takahashi; Masaya Higuchi; Toshifumi Hara; Kousuke Saito; Yuetsu Tanaka; Masayoshi Masuko; Jun Takizawa; Hirohito Sone; Masahiro Fujii
Journal:  Int J Hematol       Date:  2017-10-17       Impact factor: 2.490

5.  Pentosan Polysulfate Demonstrates Anti-human T-Cell Leukemia Virus Type 1 Activities In Vitro and In Vivo.

Authors:  Guangyong Ma; Jun-Ichirou Yasunaga; Koichi Ohshima; Tadashi Matsumoto; Masao Matsuoka
Journal:  J Virol       Date:  2019-07-30       Impact factor: 5.103

6.  Discovery and characterization of auxiliary proteins encoded by type 3 simian T-cell lymphotropic viruses.

Authors:  Jocelyn Turpin; Chloé Journo; Nga Ling Ko; Flore Sinet; Alexandre Carpentier; Amandine Galioot; Dustin Edwards; Anne-Mieke Vandamme; Louis Gazzolo; Madeleine Duc Dodon; Antoine Gessain; Fatah Kashanchi; Ivan Balansard; Romain Lacoste; Renaud Mahieux
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

7.  Permissive Sense and Antisense Transcription from the 5' and 3' Long Terminal Repeats of Human T-Cell Leukemia Virus Type 1.

Authors:  Sylvain Laverdure; Nicholas Polakowski; Kimson Hoang; Isabelle Lemasson
Journal:  J Virol       Date:  2016-01-20       Impact factor: 5.103

Review 8.  How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)?

Authors:  Charles R M Bangham; Lee Ratner
Journal:  Curr Opin Virol       Date:  2015-09-27       Impact factor: 7.090

9.  HTLV-1 bZIP factor protein targets the Rb/E2F-1 pathway to promote proliferation and apoptosis of primary CD4(+) T cells.

Authors:  A Kawatsuki; J-I Yasunaga; Y Mitobe; P L Green; M Matsuoka
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

10.  The genomic landscape of adult T cell leukemia/lymphoma.

Authors:  Carmen Vicente; Jan Cools
Journal:  Nat Genet       Date:  2015-11       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.